Sir2, an enzyme belonging to sirtuins, has been shown to be involved in the deacetylation of proteins. Researchers from the ...
Sir2, an enzyme belonging to sirtuins, has been effectively involved in the deacetylation of proteins. A tandem allosteric ...
BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of ...
The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and ...
BETHESDA, Md. - Gain Therapeutics, Inc. (NASDAQ:GANX), a $69 million market cap biotech company currently trading at $1.92 per share, announced Monday that its lead drug candidate GT-02287 showed ...
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic, reversible grade ...
Long Interspersed Nuclear Element-1 (LINE-1 or L1) is the only active, self-copying genetic element in the human ...
Investing.com -- Terns Pharmaceuticals Inc (NASDAQ:TERN) stock tumbled 14.4% in after-hours trading Tuesday after the company announced it would discontinue development of its oral GLP-1 receptor ...
As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback